What about electrochemical behaviors for aurivillius-phase bismuth tungstate? Capacitive or pseudocapacitive.

Researchers mainly explore the mechanism of pseudocapacitance through studying electrode materials with Faraday pseudocapacitive behavior. Here, we found that Bi2WO6, a typical Aurivillius phase material with pseudo-perovskite structure, showed nearly ideal pseudocapacitive behavior. The cyclic voltammetry curve is approximately rectangular in shape, with no redox peaks, which is similar to that of carbon materials. And the shape of the galvanostatic charge-discharge curve is close to an isosceles triangle. In addition, the kinetic analysis demonstrated that the electrochemical process of the A-Bi2WO6 electrode is dominated by surface processes, not diffusion. The A-Bi2WO6 electrode material presents a great volumetric specific capacitance of 466.5 F cm-3 at 0.5 A g-1. These electrochemical properties confirm that the Bi2WO6 material can serve as an ideal support material to explore pseudocapacitive energy storage. This work also provides guidance for the development of new pseudocapacitive materials.

Electrode Materials of Cobaltous Fluoride for Supercapacitor and Electrocatalysis Applications.

Herein, CoF2 was synthesized by a solvothermal method. The characterization results of the phase and morphology of the sample show that it was successfully synthesized and its morphology is composed of micron particles with uneven size and shape. The electrochemical test results of SCs in different electrolytes show that CoF2 has electrochemical activity only in alkaline electrolytes. Notably, the electrochemical behavior of CoF2 in LiOH solution is different from that in other alkaline solutions in that charge-discharge curve has a quasi-isosceles triangle shape and the CV curve has no obvious redox peak. That is, it has pseudocapacitance behavior in LiOH. Furthermore, CoF2 as catalyst for HER requires an overpotential of only 168 mV to obtain current density of 10 mA cm-2 and a Tafel slope of 116 mV dec-1 in 1 M KOH solution. This research provides a novel way to explore excellent performance electrode materials for SC and HER.

Enhancing the Kinetic Process in Biphasic Crystalline NiWO4 /Amorphous Co-B Electrode Materials toward Energy Storage with Ultrahigh Rate Performance.

Here, we report a two-phase crystalline NiWO4 /amorphous Co-B nanocomposite as an electrode material for supercapacitors, which is effectively synthesized via a simple hydrothermal method and chemical precipitation method. The obtained NiWO4 /Co-B exhibits crystal-amorphous contact, which makes it have more active sites than other crystalline-crystalline phase boundaries, thereby enhancing electron transport. The NiWO4 /Co-B electrode with the best mass ratio of crystalline and amorphous exhibits a great specific capacitance and excellent cycle durability. Compared to individual Co-B and NiWO4 , it also shows enhanced rate capability Besides, NiWO4 /Co-B/activated carbon supercapacitor device can provide a good specific capacitance and a maximum energy density of 10.92 Wh kg-1 at 200 W kg-1 . This work provides new insights to develop novel electrode materials for energy storage and conversion.

Modification of ultra-micropore dominated carbon by O/N-containing functional groups grafted for enhanced supercapacitor performances.

In our study, a simple method was employed to prepare ultra-micropore-dominated carbon materials with controllable pore size. A mass of heteroatoms was introduced by surface functional group grafting, resulting in enhanced electrochemical performance: the maximum specific capacity of 327.5 F g-1 was obtained at 0.5 A g-1 in 6 M KOH, while that of un-grafted original ultra-microporous carbon was only 188 F g-1, with long-term cycle stability (90.5% of the initial after 10 000 cycles), and excellent rate performance (over 82% at the current density from 0.5 A g-1 to 10 A g-1). The mechanism behind the improved performance was due to the presence of the introduced functional groups that improved the surface wettability of the material and provided additional redox active sites. Their synergistic effects promoted the enhanced electrochemical performance of the ultra-microporous carbon. This study provides a basis for the study of the energy storage mechanism of ultra-microporous carbon and the grafted modification of carbon materials with heteroatom-containing functional groups.

Realizing high-performance and low-cost lithium-ion capacitor by regulating kinetic matching between ternary nickel cobalt phosphate microspheres anode with ultralong-life and super-rate performance and watermelon peel biomass-derived carbon cathode.

Lithium-ion capacitors (LICs) are emerging as one of the most advanced energy storage devices by combining the virtues of both supercapacitors (SCs) and lithium-ion batteries (LIBs). However, the kinetic and capacity mismatch between anode and cathode is the main obstacle to wide applications of LICs. Therefore, the effective strategy of constructing a high-performance LIC is to improve the rate and cycle performance of the anode and the specific capacity of the cathode. Herein, the nickel cobalt phosphate (NiCoP) microspheres anode is demonstrated with robust structural integrity, high electrical conductivity, and fast kinetic feature. Simultaneously, the watermelon-peel biomass-derived carbon (WPBC) cathode is demonstrated a sustainable synthesis strategy with high specific capacity. As expected, the NiCoP exhibits high specific capacities (567 mAh g-1 at 0.1 A g-1), superior rate performance (300 mAh g-1 at 1A g-1), and excellent cycle stability (58 mAh g-1 at 5 A g-1 after 15,000 cycles). The WPBC possesses a high specific surface area (SSA) of 3303.6 m2 g-1 and a high specific capacity of 226 mAh g-1 at 0.1 A g-1. Encouragingly, the NiCoP//WPBC-6 LIC device can deliver high energy density (ED) of 127.4 ± 3.3 and 67 ± 3.8Wh kg-1 at power density (PD) of 190 and 18240 W kg-1 (76.4% capacity retention after 7000 cycles), respectively.

Crystal Phase-Controlled Synthesis of the CoP@Co2P Heterostructure with 3D Nanowire Networks for High-Performance Li-Ion Capacitor Applications.

The paramount focus in the construction of lithium-ion capacitors (LICs) is the development of anode materials with high reversible capacity and fast kinetics to overcome the mismatch of kinetics and capacity between the anode and cathode. Herein, a strategy is presented for the controllable synthesis of cobalt-based phosphides with various morphologies by adjusting the time of the phosphidation process, including 3D hierarchical needle-stacked diabolo-shaped CoP nanorods, 3D hierarchical stick-stacked diabolo-shaped Co2P nanorods, and 3D hierarchical heterostructure CoP@Co2P nanorods. 3D hierarchical nanostructures and a highly conductive project to accommodate volume changes are rational designs to achieve a robust construction, effective electron-ion transportation, and rapid kinetics characteristics, thus leading to excellent cycling stability and rate performance. Owing to these merits, the 3D hierarchical CoP, Co2P, and CoP@Co2P nanorods demonstrate prominent specific capacities of 573, 609, and 621 mA h g-1 at 0.1 A g-1 over 300 cycles, respectively. In addition, a high-performance CoP@Co2P//AC LIC is successfully constructed, which can achieve high energy densities of 166.2 and 36 W h kg-1 at power densities of 175 and 17524 W kg-1 (83.7% capacity retention after 12000 cycles). Therefore, the controllable synthesis of various simultaneously constructed crystalline phases and morphologies can be used to fabricate other advanced energy storage devices.

Boosting the performance of cobalt molybdate nanorods by introducing nanoflake-like cobalt boride to form a heterostructure for aqueous hybrid supercapacitors.

Binary transition metal oxides have received extensive attention because of their multiple oxidation states. However, due to the inherent vices of poor electronic/ionic conductivities, their practical performance as supercapacitor material is limited. Herein, a cobalt molybdate/cobalt boride (CoMoO4/Co-B) composite is constructed with cobalt boride nanoflake-like as a conductive additive in CoMoO4 nanorods using a facile water bath deposition process and liquid-phase reduction method. The effects of CoMoO4/Co-B mass ratios on its electrochemical performance are investigated. Remarkably, the CoMoO4/Co-B composite obtained at a mass ratio of 2:1 shows highly enhanced electrochemical performance relative to those obtained at other ratios and exhibits an optimum specific capacity of 436 F g-1 at 0.5 A g-1. This kind of composite could also display great rate capacity (294 F g-1 at 10 A g-1) and outstanding long cycle performance (90.5% capacitance retention over 10 000 cycles at 5 A g-1). Also, the asymmetric supercapacitor device is prepared by using CoMoO4/Co-B composite as the anode with the active carbon as the cathode. Such a device demonstrates an outstanding energy density of 23.18 Wh kg-1 and superior long-term stability with 100% initial specific capacity retained after 10,000 cycles. The superior electrochemical properties show that the CoMoO4/Co-B electrode material has tremendous potential in energy storage equipment applications.

Intravenous flurbiprofen axetil enhances analgesic effect of opioids in patients with refractory cancer pain by increasing plasma ß-endorphin.

BACKGROUND: The study aimed to investigate the analgesic effect of a combination of intravenous flurbiprofen axetil and opioids, and evaluate the relationship between refractory pain relief and plasma ß-endorphin levels in cancer patients. MATERIALS AND METHODS: A total of 120 cancer patients was randomly divided into two groups, 60 patients took orally morphine sulfate sustained-release tablets in group A, and another 60 patients receiving the combination treatment of intravenous flurbiprofen axetil and opioid drugs in group B. After 7 days, pain relief, quality of life improvement and side effects were evaluated. Furthermore, plasma ß-endorphin levels were measured by radioimmunoassay. RESULTS: With the combination treatment of intravenous intravenous flurbiprofen axetil and opioids, the total effective rate of pain relief rose to 91.4%, as compared to 82.1% when morphine sulfate sustained-release tablet was used alone. Compared with that of group A, the analgesic effect increased in group B (p=0.031). Moreover, satisfactory pain relief was associated with a significant increase in plasma ß-endorphin levels. After the treatment, plasma ß-endorphin level in group B was 62.4±13.5 pg/ml, which was higher than that in group A (45.8±11.2 pg/ml) (p<0.05). CONCLUSIONS: Our results suggest the combination of intravenous flurbiprofen axetil and opioids can enhance the analgesic effect of opioid drugs by increasing plasma ß-endorphin levels, which would offer a selected and reliable strategy for refractory cancer pain treatment.

Co-transduction of ribosomal protein L23 enhances the therapeutic efficacy of adenoviral-mediated p53 gene transfer in human gastric cancer.

Induction of murine double minute 2 (MDM2) expression is thought to be a determinant of resistance to p53 gene therapy for cancer. Previous studies have revealed that ribosomal protein L23 (RPL23) inhibits MDM2-mediated p53 degradation through direct binding to MDM2. In addition, ectopically expressed RPL23 was reported to interact with MDM2 in both the nucleus and cytoplasm, by which RPL23 indirectly inhibited MDM2-p53 binding. Based on the known molecular properties of the RPL23 protein, it was speculated that co-transduction of RPL23 may protect wild­type p53 protein from MDM2-mediated inactivation and, thus, improve the effect of delivering therapeutic exogenous p53. To test this hypothesis, we constructed a bicistronic adenoviral vector expressing both the RPL23 and p53 genes (Ad-RPL23/p53) and compared its tumor-suppressor activity in human gastric cancer with that of a single gene vector for p53 (Ad-p53). In the in vivo and in vitro experiments, we observed that treatment with Ad-RPL23/p53 resulted in a stronger antitumor response compared to that obtained using Ad-p53. Moreover, the antitumor response of the bicistronic adenovirus was obtained not only in MGC803 cells (endogenous mutant p53) but also in MKN45 cells (endogenous wild­type p53) which were initially resistant to p53 gene transfer, indicating that co-transduction of RPL23 also expanded the utility of p53 gene therapy. Furthermore, in an orthotopic nude mouse model of human gastric cancer, we found that the survival benefit was greater after Ad-RPL23/p53 treatment than after Ad-p53. Taken together, the data presented here demonstrate that co-transduction of RPL23 enhances the therapeutic efficacy of adenoviral-mediated p53 gene transfer in models of human gastric cancer and support the use of this strategy for cancer treatment.

MiR-26a regulates cell cycle and anoikis of human esophageal adenocarcinoma cells through Rb1-E2F1 signaling pathway.

Resistance to anoikis, the subtype of apoptosis induced by lack of matrix adhesion, contributes to malignant transformation and development of metastasis. MicroRNAs play key regulatory roles in tumorigenesis and metastasis. In this study, we described that miR-26a, which is usually downregulated in tumor cells, is involved in the acquisition of anoikis-resistance of human esophageal adenocarcinoma (EA) cells. Results of qRT-PCR in clinical samples showed that downregulated miR-26a expression is related to tumorigenesis and metastasis of EA. In vitro experiments determined that miR-26a directly participates in the regulation of cell cycle and anoikis of human EA OE33 cells. Further, we identified that Rb1 is the direct functional target of miR-26a, and revealed that the reduction of miR-26a expression leads to increased Rb1 protein level and thus inhibits the function of E2F1, by which it influences the phenotypes of cell cycle and anoikis. The findings we reported here presented the evidence that miR-26a may be involved in regulation of anoikis-resistance of EA cells. Targeting miR-26a may provide a novel strategy to inhibit metastasis.

Peritumoral lymphatic microvessel density is related to poor prognosis in lung adenocarcinoma: A retrospective study of 65 cases.

Although recent investigations have identified that lymphangiogenesis is associated with regional lymph node metastasis and tumor prognosis in non-small cell lung cancer (NSCLC), peritumoral lymphatic microvessel density (LMVD) and its prognostic significance in lung adenocarcinoma remain unknown. In the present study, we assessed peritumoral LMVD in lung adenocarcinoma and investigated its correlation with patient prognosis. Using immunohistochemistry (SP method), the D2-40-positive peritumoral LMVD count in lung adenocarcinoma was found to be 11.56±10.73, which was higher than intratumoral LMVD (P<0.001), and was found to be associated with lymphatic metastasis (P=0.003) and pTNM staging (P=0.046). Furthermore, a significant difference in the patient overall survival time was demonstrated between tumors with a high peritumoral LMVD and those with a low peritumoral LMVD (P=0.005). Finally, using multivariate analysis, it was determined that peritumoral LMVD, lymphatic metastasis and pTNM staging were independent prognostic factors. In conclusion, the results suggest that D2-40-positive peritumoral LMVD may predict the prognosis of lung adenocarcinoma.

Giant adenocarcinoma of unknown origin penetrating from the pelvic cavity to subcutaneous tissue: A case report and review of the literature.

In this study, we present a case of a 43-year-old female patient who was admitted to our hospital due to a giant mass on the left buttock. Imaging tests revealed that the mass was a solid-cystic tumor with a large size of 143×430×180 mm, penetrating from the pelvic cavity to the subcutaneous tissue. Pathology tests indicated a metastatic mucinous adenocarcinoma which was most likely of gastrointestinal origin. However, there was no evidence to confirm the existence of malignant changes in the gastrointestinal tract.

Tumor-associated macrophages infiltration is associated with peritumoral lymphangiogenesis and poor prognosis in lung adenocarcinoma.

Tumor-associated macrophages (TAMs) have been implicated in promoting tumor progression. Nowadays, adenocarcinoma has surpassed squamous cell carcinoma as the most frequent type of lung cancer, but in lung adenocarcinoma, the correlation of TAMs with lymphangiogenesis patients remains unclear. The aim of this study was to examine the relationship between TAMs and lymphangiogenesis and the lung adenocarcinoma patients' prognosis. Tumor specimens from 65 patients with lung adenocarcinoma were determined for TAMs count and lymphatic microvessel density (LMVD) by immunohistochemistry. A positive correlation existed between TAMs count and D2-40-positive peritumoral LMVD (r=0.069, P<0.001). TAMs infiltration was significantly associated with P-TNM staging (P=0.042) and lymph node metastasis (P=0.037), and peritumoral LMVD was correlated with lymph node metastasis (P=0.003). A significant difference in overall survival was detected not only between tumors with a high TAMs count and a low TAMs count (P=0.009) but also between tumors with a high peritumoral LMVD and a low peritumoral LMVD (P=0.005). Both TAMs count and peritumoral LMVD were independent prognostic factors for overall survival. Our results indicate that TAMs infiltration correlates with tumor lymphangiogenesis and poor survival in lung adenocarcinoma.

Induction of apoptosis and inhibition of cell migration and tube-like formation by dihydroartemisinin in murine lymphatic endothelial cells.

Dihydroartemisinin (DHA) is a semisynthesized agent from the artemisinin first extracted from the Chinese plant Artemisia annua. Previous studies have shown that artemisinin derivates, apart from their antimalarial activity, possess antitumor, antiangiogenic, and anti-inflammatory effects. In the present investigation, DHA was found to have a potent ability in influencing lymphatic endothelial cells (LECs) behavior. Murine LECs were isolated from benign lymphangiomas induced by intraperitoneal injection of incomplete Freund's adjuvant and identified by indirect immunofluorescence assay and fluorescence-activated cell sorting analysis to examine the expression of the specific marker VEGFR-3/Flt-4. When LECs were treated with DHA at 10 microg/ml, the growth of LECs was inhibited, and LECs showed typical apoptotic morphological features, with a higher apoptotic rate as compared with the controls. DHA also exerted a significant inhibitory effect on migration and tube-like formation of LECs in a dose-dependent manner. Quantitative RT-PCR further showed that DHA remarkably downregulated the expression of antiapoptotic bcl-2 mRNA, but upregulated that of the proapoptotic gene bax mRNA. In addition, DHA could strongly attenuate the mRNA and protein levels of VEGFR-3/Flt-4. In summary, these findings indicate that DHA may be useful as a potential lymphangiogenesis inhibitor under induction of cell apoptosis, inhibition of the migration, and formation of tube-like structures in LECs.

[Efficacy of NO regimen and NP regimen on advanced non-small cell lung cancer: a prospective randomized trial].

BACKGROUND & OBJECTIVE: Oxaliplatin (LOHP) is an effective drug in treatment of non-small cell lung cancer (NSCLC) with mild toxicities to gastrointestinal tract, kidney, and bone marrow. Cisplatin (DDP) plus vinorelbine (NVB) constitute the first-line regimen (NP regimen) for NSCLC. This study was to compare the short-term response, long-term outcome, and adverse events between advanced NSCLC patients received NO regimen (LOHP plus NVB) and NP regimen. METHODS: A total of 90 patients with advanced NSCLC were randomized into NO group (58 patients, 25 mg/m(2) of NVB, day 1 and day 8; 130 mg/m(2) of LOHP, day 1) and NP group (32 patients, 25 mg/m(2) of NVB, day 1 and day 8; 50 mg/m(2) of DDP, day 2 and day 3). The short-term response, long-term outcome, adverse events, and survival status of the 2 groups were observed. RESULTS: The response rates were 33.33% in NO group, and 35.48% in NP group, but no significant difference was detected between the 2 groups (P > 0.05). The clinical benefit response rate was significantly higher in NO group than in NP group (80.70% vs. 64.52%, P < 0.05). The median time to progression (TTP) was 17 weeks in NO group, and 15 weeks in NP group; the median time of remission was 21 weeks in NO group, and 19 weeks in NP group; the median survival time was 39 weeks in NO group, and 37 weeks in NP group; the 1-year survival rate was 37.93% in NO group, and 31.25% in NP group. No significant differences were detected between the 2 groups. The incidence rates of phlebitis and grade I-II peripheral neuritis were significantly higher in NO group than in NP group (77.59% vs. 50.00%, P<0.01; 43.10% vs. 15.63%, P<0.01). The incidence rate of grade III-IV nausea/vomiting was significantly higher in NP group than in NO group (31.25% vs. 3.45%, P<0.05). CONCLUSIONS: The efficacy of NO regimen on advanced NSCLC is similar to that of NP regimen, but the clinical benefit response rate is higher in NO group than in NP group. In short, NO regimen may be recommended as the first-line chemotherapy regimen for advanced NSCLC.

[A randomized trial comparing oxaliplatin plus vinorelbine versus cisplatin plus vinorelbine for the treatment of patients with advanced non-small-cell lung cancer].

OBJECTIVE: To evaluate the difference of efficacy, side-effects and quality of life in advanced non-small-cell lung cancer (NSCLC) patients treated with oxaliplatin plus vinorelbine or cisplatin plus vinorelbine. METHODS: Eligible patients were randomly assigned to NL (oxaliplatin + vinorelbine) group and NP (cisplatin + vinorelbine) group in a 2:1 ratio. In the NL group, 70 evaluable cases were treated with oxaliplatin 130 mg/m(2) i.v. on day 2, and vinorelbine 25 mg/m(2) i.v. on days 1 and 8 in 21 days per cycle. In the NP group, 32 evaluable cases were treated with cisplatin 80 mg/m(2) i.v. divided to 2 - 3 days dosing, 21 days per cycle, and vinorelbine administered by the same way as in the NL group. The response rate, time to progression (TTP), one-year survival, side-effects and the quality of life were observed. RESULTS: The response rate was 35.7% vs. 43.8% (P = 0.4), median TTP was 4.7 months vs. 5.5 months (P = 0.6), one-year survival rate was 38.5% vs. 58.6% (P = 0.07) in the NL and NP groups, respectively. Grade I-II neuro-sensory toxicity occurred significantly more frequent in NL group than in NP group (68.4% vs. 36.4%, P = 0.0017). However, Grade I-II granulocytopenia was significantly less occurred in NL group than in NP group (49.4% vs. 70.6%, P = 0.037). There was no statistically difference between the two groups regarding quality of life. CONCLUSION: Due to good efficacy and tolerability, the NL regimen offered a new candidate for treating advanced NSCLC.

[Prospective randomized study of HMVP, MVP, and HVP regimens in treatment of advanced non-small cell lung cancer].

BACKGROUND & OBJECTIVE: Non-small cell lung cancer (NSCLC) is hyposensitive to the normal first and second-line chemotherapy regimens. Camptothecin derivative is becoming a hot point in the treatment of advanced NSCLC. The objective of this article was to evaluate the response, toxicity, and survival time of HMVP, MVP, and HVP regimens (detail in below) in the treatment of advanced NSCLC. METHODS: A total of 134 cases with advanced NSCLC was randomized into three groups: HMVP group [46 patients, hydroxycamptothecin (HCPT) 12 mg/m(2) from d1 to d5, mitomycin C (MMC) 6 mg/m(2) d1, vindesine (VDS) 2.5-3 mg/m(2) d1 and d8, cisplatin (DDP) 50 mg/m(2) d2 and d3], MVP group (44 patients, MMC, VDS and DDP were the same as HMVP group) and HVP group (44 patients, HCPT, VDS, DDP were the same as HMVP group). RESULTS: The response rates were 39.54% (17/43), 35.57% (15/42), and 26.19% (11/42) in HMVP, MVP, and HVP groups, respectively; no significant difference was detected among the three groups (P >0.05). No significant difference was detected in the median time of remission, median survival time, and 1-, 2-year survival rates among the three groups. Moreover, no significant difference was detected in grade III-IV leukopenia, grade III-IV thrombocytopenia, grade III-IV nausea and vomiting and grade III-IV constipation among the three groups. CONCLUSION: The response rate of MVP regimen is slightly lower than that of HMVP regimen, but HMVP regimen do not show obvious superiority. It may increase toxicities such as leukopenia, nausea/vomiting, and constipation. The response rate of HVP regimen is slightly lower than that of MVP regimen.